Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
| Language | Translation |
|---|---|
English
|
Pulmonary eosinophilia, not elsewhere classified |
French
|
รosinophilie pulmonaire, non classรฉe ailleurs |
| Level | Code | Title | |
|---|---|---|---|
| 1 | X | Diseases of the respiratory system | |
| 2 | J80-J84 | Other respiratory diseases principally affecting the interstitium | |
| 3 | J82 | Pulmonary eosinophilia, not elsewhere classified |
| Active Ingredient | Description | |
|---|---|---|
| Mepolizumab |
Mepolizumab is a humanised monoclonal antibody (IgG1, kappa), which targets human interleukin-5 (IL-5) with high affinity and specificity. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophils. Mepolizumab is indicated as an add-on treatment for severe refractory eosinophilic asthma. |
|
| Reslizumab |
Reslizumab is a humanised monoclonal antibody (IgG4, ฮบ) against the human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5 and interferes with IL-5 binding to its cell-surface receptor. IL-5 is a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. Reslizumab binds human IL-5 with picomolar affinity blocking its biological function; consequently survival and activity of eosinophils are reduced. |
